A Neuralink in the Pharmaceutical Field: A Comprehensive Review of Brain–Computer Interface Applications in Drug Development and Neurological Therapy

Karri Kishore Karri; Umamaheshwari M; Dhanalaxmi P; Tejaswi G; SAILAJA V; Ramaiah Maddi

doi:10.37022/jis.v9i1.132

Karri Kishore Karri Department of Pharmacy Practice, Maharajah’s College of Pharmacy, Phool Baugh, Vizianagaram – 535002, A.P., India
M.Umamaheshwari Department of Pharmacy Practice, Maharajah’s College of Pharmacy, Phool Baugh, Vizianagaram – 535002, A.P., India
P.Dhanalaxmi Department of Pharmacy Practice, Maharajah’s College of Pharmacy, Phool Baugh, Vizianagaram – 535002, A.P., India
G.Tejaswi Department of Pharmacy Practice, Maharajah’s College of Pharmacy, Phool Baugh, Vizianagaram – 535002, A.P., India
V.Sailaja Department of Pharmacy Practice, Maharajah’s College of Pharmacy, Phool Baugh, Vizianagaram – 535002, A.P., India
Ramaiah Maddi Department of Pharmacognosy, Maharajah’s College of Pharmacy, Phool Baugh, Vizianagaram – 535002, A.P., India

DOI https://doi.org/10.37022/jis.v9i1.132

Abstract

Recent developments in neurotechnology have created new possibilities for advancing biomedical and pharmaceutical research. One of the most promising innovations is the brain–computer interface (BCI), a technology that enables direct communication between the human brain and external computing systems. Neuralink, a neurotechnology company established by Elon Musk, is developing high-bandwidth implantable neural interfaces capable of both recording and stimulating brain activity. These devices use ultra-thin electrode threads implanted into the brain to capture neuronal signals and transmit them wirelessly to computers for analysis. Such technology has significant implications for pharmaceutical science, particularly in areas such as neurological drug discovery, personalized treatment strategies, and real-time therapeutic monitoring. By providing continuous observation of neural responses to medications, Neuralink may accelerate the development of new drugs, enhance clinical trial evaluation, and support precision medicine approaches for neurological conditions including Parkinson’s disease, epilepsy, major depressive disorder, and Alzheimer’s disease. This review paper analyzes the technological principles behind Neuralink systems and discusses their potential applications in pharmaceutical research. Additionally, it evaluates the benefits, challenges, ethical considerations, and future research directions associated with integrating brain–computer interface technology into pharmaceutical development.

Keywords: Neuralink, Brain-Computer Interface, Neurotechnology, Drug Development, Pharmaceutical Research, Personalized Medicine

References

1. Musk E, et al. An integrated brain–machine interface platform with thousands of channels. J Med Internet Res. 2019.
2. Shih JJ, Krusienski DJ, Wolpaw JR. Brain–computer interfaces in medicine. Mayo Clin Proc. 2012.
3. Lavazza A. Neuralink’s brain–computer interfaces: medical innovations and future prospects. Front Hum Dyn. 2025.
4. Deng Q, et al. Application and future directions of brain–computer interfaces. Neurotechnol Rev. 2025.
5. Parikh PM. Neuralink and brain–computer interface: exciting times ahead. J Clin Med. 2024.
6. Sah SK. Impact of brain–computer interfaces in healthcare. J Biomed Pharm Sci. 2024.
7. Boonstra JT. Ethical imperatives in the commercialization of brain–computer interfaces. Neuroethics Rev. 2025.
8. Huang J, et al. Bibliometric analysis of brain–computer interface applications. J Multidiscip Healthc. 2025.
9. Alkaff ZA, et al. Applications of brain–computer interface in healthcare. In: IntechOpen; 2024.
10. Neuralink. Brain–computer interface technology overview. Neuralink Official Website.
11. Wolpaw JR, Wolpaw EW. Brain–computer interfaces: principles and practice. Oxford: Oxford University Press; 2012.
12. Nicolelis MAL, Lebedev MA. Principles of neural ensemble physiology underlying the operation of brain–machine interfaces. Nat Rev Neurosci. 2017.
13. Jackson A, Zimmermann JB. Neural interfaces for the brain and spinal cord. Cold Spring Harb Perspect Med. 2012.
14. Lebedev MA, Nicolelis MAL. Brain–machine interfaces: past, present and future. Trends Neurosci. 2006.
15. Borton D, Yin M, Aceros J, Nurmikko A. An implantable wireless neural interface for recording cortical circuit dynamics. Nat Commun. 2013.
16. Steinmetz NA, et al. Neuropixels 2.0: a miniaturized high-density probe for stable, long-term brain recordings. Science. 2021.
17. Bouton CE, et al. Restoring cortical control of functional movement in a human with quadriplegia. Nature. 2016.
18. Fetz EE. Restoring motor function with bidirectional neural interfaces. Prog Brain Res. 2015.
19. Schwartz AB, Cui XT, Weber DJ, Moran DW. Brain-controlled interfaces: movement restoration with neural prosthetics. Neuron. 2006.
20. Donoghue JP. Connecting cortex to machines: recent advances in brain interfaces. Nat Neurosci. 2002.
21. Farina D, Aszmann O. Bionic limbs: clinical reality and academic promises. Sci Transl Med. 2014.
22. Chaudhary U, Birbaumer N, Ramos-Murguialday A. Brain–computer interfaces for communication and rehabilitation. Nat Rev Neurol. 2016.
23. Rao RPN. Brain–computer interfacing: an introduction. Cambridge: Cambridge University Press; 2013.
24. Velliste M, et al. Cortical control of a prosthetic arm for self-feeding. Nature. 2008.
25. Birbaumer N. Breaking the silence: brain–computer interfaces for communication and motor control. Psychophysiology. 2006.
26. Lebedev MA, Nicolelis MAL. Brain–machine interfaces: from basic science to neuroprostheses and neurorehabilitation. Physiol Rev. 2017.
27. Flesher SN, et al. Intracortical microstimulation of human somatosensory cortex. Sci Transl Med. 2016.
28. Collinger JL, et al. High-performance neuroprosthetic control by an individual with tetraplegia. Lancet. 2013.
29. Vansteensel MJ, et al. Fully implanted brain–computer interface in a locked-in patient. N Engl J Med. 2016.
30. Shenoy KV, Carmena JM. Combining decoder design and neural adaptation in brain–machine interfaces. Neuron. 2014.